Reviewing PTC Therapeutics (NASDAQ:PTCT) & Palatin Technologies (OTCMKTS:PTNT)

Palatin Technologies (OTCMKTS:PTNT) and PTC Therapeutics (NASDAQ:PTCT) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, valuation, profitability, dividends, risk and analyst recommendations.

Earnings & Valuation

This table compares Palatin Technologies and PTC Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palatin Technologies	$4.49 million	0.22	-$29.74 million	($60.00)	-0.41
PTC Therapeutics	$1.73 billion	3.50	$682.64 million	($0.58)	-125.21

PTC Therapeutics has higher revenue and earnings than Palatin Technologies. PTC Therapeutics is trading at a lower price-to-earnings ratio than Palatin Technologies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Palatin Technologies and PTC Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Palatin Technologies	N/A	N/A	-365.57%
PTC Therapeutics	-3.80%	-362.45%	-1.32%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Palatin Technologies and PTC Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palatin Technologies	0	0	0	0	0.00
PTC Therapeutics	2	2	9	1	2.64

PTC Therapeutics has a consensus price target of $98.55, indicating a potential upside of 35.69%. Given PTC Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe PTC Therapeutics is more favorable than Palatin Technologies.

Volatility & Risk

Palatin Technologies has a beta of -1.47, indicating that its share price is 247% less volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500.

Institutional & Insider Ownership

11.5% of Palatin Technologies shares are held by institutional investors. 10.5% of Palatin Technologies shares are held by insiders. Comparatively, 5.3% of PTC Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

PTC Therapeutics beats Palatin Technologies on 10 of the 15 factors compared between the two stocks.

About Palatin Technologies

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.

About PTC Therapeutics

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.